Drug Profile
Research programme: therapeutic proteins - Multicell Technologies
Alternative Names: Recombinant I(alpha)Ip - Multicell Technologies; Therapeutic protein for sepsis - Multicell TechnologiesLatest Information Update: 08 Jun 2010
Price :
$50
*
At a glance
- Originator MultiCell Technologies Inc
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 19 Oct 2005 Preclinical trials in Sepsis in USA (unspecified route)